Vibeke V.
- Country
- Belgium
- Department
- Hematology
Research Overview
- Phase 3 Randomized Study of Pirtobrutinib vs. Investigator-Selected BTK Inhibitor in Previously Treated BTK Inhibitor-Naïve Mantle Cell Lymphoma
- Phase 3 Randomized Study of Bendamustine, Rituximab, and Acalabrutinib in Untreated Mantle Cell Lymphoma
- Phase 3 Randomized Study of Epcoritamab Plus R-CHOP Versus R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients
Data & Insights
Has run more than one trial at 54 of 226 partner sites.
Specializations
Lymphoma Treatment Innovation
This investigator specializes in developing advanced therapeutic approaches for mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL), with particular focus on novel treatment combinations and targeted therapies.
- BTK Inhibitor Therapies
- Combination Treatment Strategies
- Immunotherapy Applications
Their work extends to evaluating innovative therapeutic agents including pirtobrutinib, acalabrutinib, and epcoritamab.
Advanced Hematologic Malignancies
The investigator focuses on treating refractory blood cancers and exploring novel therapeutic pathways, particularly in addressing treatment-resistant forms of lymphoma.
- Targeted Molecular Therapies
- Novel Drug Development
- Treatment Resistance Mechanisms
Their research includes evaluation of innovative compounds like zilovertamab vedotin and BGB-11417 for resistant disease.
Treatment Protocol Development
The investigator works on optimizing therapeutic protocols for lymphoid malignancies, with emphasis on combining established treatments with newer targeted agents.
- Combination Therapy Optimization
- Treatment Sequencing Strategies
- Long-term Disease Management
Their expertise includes developing protocols incorporating autologous stem cell transplantation and maintenance therapy approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.